Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta‐analysis
Authors:
- 20 May 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (3) , 908-922
Abstract
Nonabsorbable disaccharides (NADs) have been used to treat hepatic encephalopathy (HE) since 1966. However, a Cochrane Review, published in 2004, found insufficient evidence to recommend their use in this context. This updated systematic review evaluates the effects of the NADs, lactulose and lactitol, for the treatment and prevention of HE in patients with cirrhosis. Thirty‐eight randomized controlled trials, involving 1,828 patients, were identified through electronic and manual searches; 31 randomized controlled trials looked at the treatment of HE, while seven looked at its primary/secondary prevention. Random‐effects meta‐analyses showed that, compared to placebo/no intervention, NADs had a beneficial effect on HE (relative risk [RR] = 0.63, 95% confidence interval [CI] 0.53‐0.74, number needed to treat [NNT] = 4) and serious liver‐related adverse events such as liver failure, variceal bleeding, serious infections, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26‐0.69, NNT = 50). Treatment was also associated with a reduction in mortality in patients with overt HE (RR = 0.36, 95% CI 0.14‐0.94, NNT = 20), although not in patients with minimal HE. Meta‐analyses of the prevention randomized controlled trials showed that NADs prevented the development of HE (RR = 0.47, 95% CI 0.33‐0.68, NNT = 6), the risk of developing serious liver‐related adverse events (RR = 0.48, 95% CI 0.33‐0.70, NNT = 6), and reduced mortality (RR = 0.63, 95% CI 0.40‐0.98, NNT = 20). Use of NADs was associated with nonserious gastrointestinal adverse events. There were no differences in the efficacy or safety of lactulose and lactitol. Conclusions: NADs have beneficial effects in the treatment and prevention of HE; their use, in this context, confers additional benefits including a reduction in serious liver‐related morbidities and all‐cause mortality. (Hepatology 2016;64:908‐922)Keywords
This publication has 43 references indexed in Scilit:
- Lactulose Is Highly Potential in Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: Results of a Controlled Randomized TrialDigestion, 2013
- Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactuloseJournal of Gastroenterology and Hepatology, 2012
- A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpointsStatistics in Medicine, 2005
- Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled studyJournal of Hepatology, 2005
- Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patientsJournal of Hepatology, 1989
- Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathyJournal of Hepatology, 1988
- Lactitol versus lactulose in the treatment of chronic hepatic encephalopathyJournal of Hepatology, 1987
- Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE)Journal of Hepatology, 1986
- Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathyDigestive Diseases and Sciences, 1977
- Treatment of chronic portal-systemic encephalopathy with lactuloseThe American Journal of Medicine, 1971